Login to myESAIC Membership


The ESAIC is dedicated to supporting professionals in anaesthesiology and intensive care by serving as the hub for development and dissemination of valuable educational, scientific, research, and networking resources.



The ESAIC hosts the Euroanaesthesia and Focus Meeting congresses that serve as platforms for cutting-edge science and innovation in the field. These events bring together experts, foster networking, and facilitate knowledge exchange in anaesthesiology, intensive care, pain management, and perioperative medicine. Euroanaesthesia is one of the world’s largest and most influential scientific congresses for anaesthesia professionals. Held annually throughout Europe, our congress is a contemporary event geared towards education, knowledge exchange and innovation in anaesthesia, intensive care, pain and perioperative medicine, as well as a platform for immense international visibility for scientific research.


Professional Growth

The ESAIC's mission is to foster and provide exceptional training and educational opportunities. The ESAIC ensures the provision of robust and standardised examination and certification systems to support the professional development of anaesthesiologists and to ensure outstanding future doctors in the field of anaesthesiology and intensive care.



The ESAIC aims to advance patient outcomes and contribute to the progress of anaesthesiology and intensive care evidence-based practice through research. The ESAIC Clinical Trial Network (CTN), the Academic Contract Research Organisation (A-CRO), the Research Groups and Grants all contribute to the knowledge and clinical advances in the peri-operative setting.

Learn more about the ESAIC Clinical Trial Network (CTN) and the associated studies.


EU Projects

The ESAIC is actively involved as a consortium member in numerous EU funded projects. Together with healthcare leaders and practitioners, the ESAIC's involvement as an EU project partner is another way that it is improving patient outcomes and ensuring the best care for every patient.


Patient Safety

The ESAIC aims to promote the professional role of anaesthesiologists and intensive care physicians and enhance perioperative patient outcomes by focusing on quality of care and patient safety strategies. The Society is committed to implementing the Helsinki Declaration and leading patient safety projects.



To ESAIC is committed to implementing the Glasgow Declaration and drive initiatives towards greater environmental sustainability across anaesthesiology and intensive care in Europe.



The ESAIC works in collaboration with industry, national societies, and specialist societies to promote advancements in anaesthesia and intensive care. The Industry Partnership offers visibility and engagement opportunities for industry participants with ESAIC members, facilitating understanding of specific needs in anaesthesiology and in intensive care. This partnership provides resources for education and avenues for collaborative projects enhancing science, education, and patient safety. The Specialist Societies contribute to high-quality educational opportunities for European anaesthesiologists and intensivists, fostering discussion and sharing, while the National Societies, through NASC, maintain standards, promote events and courses, and facilitate connections. All partnerships collectively drive dialogue, learning, and growth in the anaesthesiology and intensive care sector.



Guidelines play a crucial role in delivering evidence-based recommendations to healthcare professionals. Within the fields of anaesthesia and intensive care, guidelines are instrumental in standardizing clinical practices and enhancing patient outcomes. For many years, the ESAIC has served as a pivotal platform for facilitating continuous advancements, improving care standards and harmonising clinical management practices across Europe.



With over 40 years of publication history, the EJA (European Journal of Anaesthesiology) has established itself as a highly respected and influential journal in its field. It covers a wide range of topics related to anaesthesiology and intensive care medicine, including perioperative medicine, pain management, critical care, resuscitation, and patient safety.



Becoming a member of ESAIC implies becoming a part of a vibrant community of nearly 8,000 professionals who exchange best practices and stay updated on the latest developments in anaesthesiology, intensive care and perioperative medicine. ESAIC membership equips you with the tools and resources necessary to enhance your daily professional routine, nurture your career growth, and play an active role in advancing anaesthesiology, intensive care and perioperative medicine.

Membership opportunities
at the ESAIC

Newsletter 2023

Newsletter July 2023: Follow up on the two ESAIC Grant winners from 2020 Young Investigator grants

In this detailed review, we explore the progress and outcomes of two noteworthy research projects that received the Young Investigator Start-up Grants from the ESAIC in 2020. Francesca Dalla Corte from Italy and Christina Massoth from Germany were the recipients of these grants, which aimed to promote innovative research in the fields of anaesthesiology and intensive care. The research projects funded by these grants have generated significant interest within the medical community.

ESAIC Young Investigator Start-up Grant 2020

Adherence to AKI guidelines in clinical practice – still a long way to go?

Christina Massoth

More than a decade ago, the Kidney Disease Improving Global Outcomes (KDIGO) guidelines proposed a care bundle comprising six measures for patients at risk for or with acute kidney injury (AKI). ​1​ Ever since, a growing body of evidence consisting of quality improvement initiatives and randomized controlled trials emerged, supporting the efficacy of this care bundle to reduce the incidence of moderate and severe AKI. ​2–5​

Since a causal treatment for AKI remains to be found, implementing the KDIGO recommendations represents the therapeutic mainstay to mitigate the morbidity and mortality associated with AKI. Patients undergoing cardiac surgery have a particularly high risk of developing postoperative AKI, with an incidence of 20% to 40%. ​6,7​ To assess guideline compliance in clinical practice in this at-risk population, we conducted this observational study at six international institutions. Our primary endpoint was the proportion of cardiac surgery patients receiving the complete care bundle consisting of the following measures: discontinuation of nephrotoxic medication when possible, tight glycemic control, close monitoring of serum creatinine and urine output, optimization of hemodynamic parameters and volume status, implementation of functional hemodynamic monitoring and avoidance of radiocontrast agents.

In total, 537 patients undergoing cardiac procedures were enrolled in the study, of whom 27.2% developed AKI within 72 hours after surgery. The complete care bundle of all six measures was implemented in 0.4% of patients. Nephrotoxic drugs were discontinued in 15.6% of patients, hyperglycemia was avoided in 39.6%, and another 6.3% received intensified monitoring of renal function. Volume status and hemodynamics were optimized in 57.4%, afunctional hemodynamic monitoring was applied in 43.9%, and radiocontrast agents were successfully avoided in 95.3%. Patients received, on average, 2.6 (SD 1.0) measures of the bundle irrespective of whether they developed AKI or not (p=0.854). ​8​

Our findings exposed a very low adherence to the measures recommended by the KDIGO guidelines in patients undergoing cardiac surgery. Poor compliance is a well-known problem in clinical care and has been described extensively for some conditions, such as treating sepsis. ​9,10​ Similarly, our survey implies a need for educational programs and quality improvement initiatives to enhance the implementation of the KDIGO guidelines in clinical routine, thereby decreasing the financial costs and morbidity associated with AKI.


  1. Kellum JA, Lameire N, Aspelin P et al. KDIGO Clinical Practice Guideline for Acute Kidney Injury 2012. Kidney International Supplements 2012; 2:1–138.
  2. Göcze I, Jauch D, Götz M, et al. Biomarker-guided Intervention to Prevent Acute Kidney Injury After Major Surgery: The Prospective Randomized BigpAK Study. Annals of surgery 2018; 267:1013–1020.
  3. Meersch M, Schmidt C, Hoffmeier A, et al. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high-risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Medicine 2017; 43:1551–1561.
  4. Zarbock A, Küllmar M, Ostermann M, et al. Prevention of Cardiac Surgery-Associated Acute Kidney Injury by Implementing the KDIGO Guidelines in High-Risk Patients Identified by Biomarkers: The PrevAKI-Multicenter Randomized Controlled Trial. Anaesthesia and analgesia 2021; 133:292–302.
  5. Engelman DT, Crisafi C, Germain M, et al. Using urinary biomarkers to reduce acute kidney injury following cardiac surgery. Journal of Thoracic and Cardiovascular Surgery 2020; 160:1235-1246.e2.
  6. Hu J, Chen R, Liu S, et al. Global Incidence and Outcomes of Adult Patients With Acute Kidney Injury After Cardiac Surgery: A Systematic Review and Meta-Analysis. Journal of Cardiothoracic and vascular anaesthesia 2016; 30:82–9.
  7. Lagny M-G, Jouret F, Koch J-N, et al. Incidence and outcomes of acute kidney injury after cardiac surgery using either criteria of the RIFLE classification. BMC nephrology 2015; 16:76.
  8. Massoth C, Küllmar M, Moncho AP, et al. Implementation of the Kidney Disease Improving Global Outcomes guidelines for the prevention of acute kidney injury after cardiac surgery: An international cohort survey. European Journal of Anaesthesiology 2023.
  9. Leone M, Ragonnet B, Alonso S, et al. Variable compliance with clinical practice guidelines was identified in a 1-day audit at 66 French adult intensive care units. Critical care medicine 2012; 40:3189–95.
  10. Bitton E, Zimmerman S, Azevedo LCP, et al. An international survey of adherence to Surviving Sepsis Campaign Guidelines 2016 regarding fluid resuscitation and vasopressors in the initial management of septic shock. Journal of critical care 2022; 68:144–154.

ESAIC Young Investigator Start-up Grant 2020

An ongoing randomized controlled trial on High Flow Nasal Cannula use after thoracic surgery: any effect on diaphragmatic function and postoperative pulmonary complications?

Dalla Corte F, Fogagnolo A, Ragazzi R, Benetto G, De Paoli G, Piccioni F, Volta CA, Spadaro S

Background and Goal of Study: Postoperative diaphragmatic dysfunction (DDys) is frequent after thoracic surgery (TS) and is associated with a higher incidence of postoperative pulmonary complications (PPCs) [1]. PPCs incidence after thoracic surgery ranges from 19 to 59%. It leads to increased healthcare costs, primarily due to increased length of stay (LOS) and intensive care unit (ICU) admission. 

The ultrasound (US) technique has recently emerged as a point-of-care tool to detect DDys [2]. High Flow Nasal Cannula (HFNC) is a non-invasive respiratory support that can improve oxygenation and reduce the work of breathing [3]. However, in recent literature, there are no clear indications of HFNC use in the perioperative setting [4]. We hypothesized that HFNC could reduce the prevalence of DDys after we assessed TS and reduce the incidence of PPCs compared to standard oxygenation therapy (SOT). 

Materials and Methods: Patients ≥ 18 years old scheduled for major lung resection surgery in video-assisted TS were enrolled. Two hours after extubation (T0), patients were randomized to receive either HFNC or SOT for 24 hours. The diaphragmatic function was assessed by ultrasound on the first (T1) and second (T2) postoperative day. Both diaphragmatic displacement (DD) and thickening fraction (TF) were assessed bilaterally with DD < 1 cm and TF < 30%, indicating DDys [5]. A strong diaphragmatic effort was defined as a TF > 40% [6]. The incidence of PPCs was recorded daily from the 1st to the 7th postoperative day. Postoperative analgesia was ensured with acetaminophen, NSAIDs boluses, and morphine as adjunctive therapy if the pain Visual Analogic Score (VAS) was > 4. Patients’ comfort (1 poor to 5 excellent) and Borg dyspnoea scale were also assessed. 

Results and Discussion: A total of 93 patients were included, 44 in the HFNC and 49 in the SOT groups. The total sample size is expected to be 116 patients (58 per group); so far, seven patients have been lost to follow-up. Patients had mostly an ASA score of 3 (75/94, 80%), and the median ARISCAT score was 49 [42-49]. The clinical characteristics of the two groups were similar. 

A bilateral DD < 1 cm was found in 20% and 13% of patients at T1 and T2, respectively. A bilateral TF < 30% was found in 14% and 9% of patients at T1 and T2, respectively. No statistically significant differences were found between the two groups. 

On the operated side, the prevalence of TF < 30% was comparable between the two groups both at T1 (35% vs 39%, p=.708) and at T2 (24% vs 17%, p=.414). A strong diaphragmatic effort of the not operated side was less frequent in the HFNC vs SOT group both at T1 (43% vs 55%, p=.244) and T2 (54% vs 61%, p=.454). 

VAS pain scale ranged between 1 and 7 at T1 and 1 and 3 at T2, with no statistically significant differences between the two groups. Comfort was comparable between the two groups ranging between 2 and 5 overall. The Borg dyspnoea score was comparable as well. 

PPCs incidence was 44% (19/43) in the HFNC group vs 63% (31/49) in the SOT group (p = .067). 

Conclusion(s): HFNC therapy is a useful and tolerable device after TS. The effect on diaphragmatic function is still unclear, and its ability to reduce Ddys is still under debate. Diaphragmatic ultrasound and its cut-off for diaphragmatic dysfunction should be used cautiously in the perioperative setting. Therefore, additional studies should be performed to assess whether HFNC might reduce Ddys prevalence and PPCs incidence. 


  1. Miskovic A, Lumb AB. Br J Anaesth 2017;118:317-334;
  2. Spadaro S, Grasso S, Dres M et al. Anesthesiology 2019;131:266–278;
  3. Mauri T, Wang YM, Dalla Corte F et al. Open Access Emerg Med 2019;11:109-120.
  4. Oczkowski S, Ergan B, Bos L, et al. Eur Respir J 2022;59:2101574.
  5. Zambon M, Greco M, Bocchino S et al. Intensive Care Med 2017;43:29–38.
  6. Umbrello M, Formenti P, Longhi D, et al. Crit Care 2015;19:161.

Funding: The present study was funded by the EASIC Young Investigator Start-up Grant 2020.

Figure 1. Two representative pictures in M-mode ultrasound of diaphragmatic displacement (a.) and thickening fraction (b.)

Figure 1. Two representative pictures in M-mode ultrasound of diaphragmatic displacement (a.) and thickening fraction (b.)

[maxbutton id=”1″ url=”https://www.esaic.org/newsletter/” text=”Read the Newsletter”]